 Liposarcoma
"Liposarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)
| Descriptor ID |
D008080
|
| MeSH Number(s) |
C04.557.450.550.420 C04.557.450.795.465
|
| Concept/Terms |
Liposarcoma, Dedifferentiated- Liposarcoma, Dedifferentiated
- Dedifferentiated Liposarcoma
- Dedifferentiated Liposarcomas
- Liposarcomas, Dedifferentiated
Liposarcoma, Pleomorphic- Liposarcoma, Pleomorphic
- Liposarcomas, Pleomorphic
- Pleomorphic Liposarcoma
- Pleomorphic Liposarcomas
|
Below are MeSH descriptors whose meaning is more general than "Liposarcoma".
Below are MeSH descriptors whose meaning is more specific than "Liposarcoma".
This graph shows the total number of publications written about "Liposarcoma" by people in this website by year, and whether "Liposarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2015 | 2 | 0 | 2 | | 2016 | 1 | 1 | 2 | | 2017 | 2 | 0 | 2 | | 2019 | 2 | 0 | 2 | | 2020 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Liposarcoma" by people in Profiles.
-
Gounder M, Abdul Razak AR, Gilligan AM, Leong H, Ma X, Somaiah N, Chawla SP, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Shah J, Shacham S, Kauffman M, Riedel RF, Attia S. Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncol. 2021 Aug; 17(22):2923-2939.
-
Furlan K, Miller I, Rohra P, Mir F, Ocampo Gonzalez FA, Gattuso P. Well-differentiated liposarcoma primary from thymic stroma: Case report and literature review. Exp Mol Pathol. 2020 10; 116:104517.
-
Jones RL, Maki RG, Patel SR, Wang G, McGowan TA, Shalaby WS, Knoblauch RE, von Mehren M, Demetri GD. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer. 2019 Dec 15; 125(24):4435-4441.
-
Chamberlain FE, Wilding C, Jones RL, Huang P. Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Expert Opin Investig Drugs. 2019 Jun; 28(6):505-511.
-
Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol. 2017 Oct 20; 35(30):3433-3439.
-
Setola E, Noujaim J, Benson C, Chawla S, Palmerini E, Jones RL. Eribulin in advanced liposarcoma and leiomyosarcoma. Expert Rev Anticancer Ther. 2017 08; 17(8):717-723.
-
Jones RL. Understanding sarcomas and other rare tumors: an interview with Robin L Jones. Future Oncol. 2017 Feb; 13(5):391-394.
-
Thway K, Jones RL, Noujaim J, Zaidi S, Miah AB, Fisher C. Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies. Adv Anat Pathol. 2016 Jan; 23(1):30-40.
-
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10; 34(8):786-93.
-
Baldini EH, Abrams RA, Bosch W, Roberge D, Haas RLM, Catton CN, Indelicato DJ, Olsen JR, Deville C, Chen YL, Finkelstein SE, DeLaney TF, Wang D. Retroperitoneal Sarcoma Target Volume and Organ at Risk Contour Delineation Agreement Among NRG Sarcoma Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):1053-1059.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|